Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$35.84

1.41 (4.10%)

07:28
05/19/17
05/19
07:28
05/19/17
07:28

Sarepta worked with parents to get FDA approval for eteplirsen, WSJ says

After trial data for Duchenne muscular dystrophy treatment eteplirsen proved inconclusive, Sarepta Therapeutics worked with parents of sick boys to provide testimony to the Food and Drug Administration supporting the drug's approval, the Wall Street Journal reports, citing parents, company managers and a Sarepta consultant. An FDA advisory committee, the majority of which didn't know Sarepta's involvement with the families, voted against approval 7-6 last year, however it was later overturned. Reference Link

SRPT Sarepta
$35.84

1.41 (4.10%)

05/18/17
PIPR
05/18/17
NO CHANGE
Target $43
PIPR
Overweight
Piper sees limited impact on Sarepta sales from FDA vote
Piper Jaffray analyst Edward Tenthoff sees a limited impact on sales from the FDA's unanimous vote allowing the use of central venous catheters to administer exon skipping drugs SRP-4045 and SRP-4053 in the Phase III ESSENCE trial. The use of IV ports will benefit DMD boys experiencing pain and trauma related to intravenous injection, and potentially lower discontinuation rates, but not impact Exondys51 sales in the near-term, Tenthoff tells investors in a research note. He keeps an Overweight rating on Sarepta Therapeutics with a $43 price target.
05/12/17
PIPR
05/12/17
NO CHANGE
Target $43
PIPR
Overweight
Sarepta panel should not impact planned interim analysis, says Piper Jaffray
After the FDA posted briefing documents ahead of a joint meeting on May 18 to vote on a parent's request for the inclusion of alternative venous access device in Sarepta's Phase III ESSENCE study of SRP-4045 and SRP-4053, Piper Jaffray analyst Edward Tenthoff said the decision should not impact the planned interim efficacy analysis after 48-week data are available, but a "Yes" vote would be beneficial for DMD boys and potentially lower discontinuation rates. He maintains his $43 price target and Overweight rating on Sarepta shares.
04/28/17
LEER
04/28/17
NO CHANGE
Target $52
LEER
Outperform
Sarepta price target raised to $52 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Sarepta to $52 from $47 after the company reported $16.3M in Exondys51 sales in Q1 that beat estimates and easily surpassed the company's guidance. The analyst reiterates an Outperform rating on the shares.
04/26/17
JANY
04/26/17
NO CHANGE
Target $65
JANY
Buy
Janney sees Sarepta selling off without material guidance raise
Going into tomorrow's earnings report from Sarepta Therapeutics, the Street is expecting a significant increase to FY17 guidance, which may not materialize, Janney Capital analyst Debjit Chattopadhyay tells investors in a pre-earnings research note. The FY17 consensus estimate for Exondys51 sales is $96M versus management's guidance of $80M-plus, the analyst points out. Chattopadhyay believes Sarepta shares could be pressured if guidance is not materially higher than the consensus since the stock is up $7 since April 11. The analyst continues to like Sarepta's intermediate to long-term outlook and recommends buying the shares on any meaningful pullbacks. Chattopadhyay has a Buy rating on the shares with a $65 fair value estimate. Sarepta in morning trading is down 58c to $35.23.

TODAY'S FREE FLY STORIES

ORLY

O'Reilly Automotive

$187.43

0.58 (0.31%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
O'Reilly Automotive reports Q2 EPS $3.10, consensus $2.89 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ASGN

On Assignment

$51.71

-1.57 (-2.95%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
On Assignment sees Q3 adjusted EPS 73c-76c, consensus 80c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CNO

CNO Financial

$21.75

-0.52 (-2.34%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
CNO Financial reports Q2 EPS 48c, consensus 37c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BWLD

Buffalo Wild Wings

$122.65

-1.05 (-0.85%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Buffalo Wild Wings »

Buffalo Wild Wings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

  • 11

    Sep

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:34
07/26/17
07/26
16:34
07/26/17
16:34
Hot Stocks
Whirlpool increases share repurchase authorization to $2.35B »

"Our strong free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRE

Duke Realty

$28.42

0.69 (2.49%)

16:34
07/26/17
07/26
16:34
07/26/17
16:34
Earnings
Breaking Earnings news story on Duke Realty »

Duke Realty sees 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BXS

BancorpSouth

$30.25

-1 (-3.20%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Hot Stocks
BancorpSouth raises quarterly dividend 12% to 14c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 18

    Sep

DRE

Duke Realty

$28.42

0.69 (2.49%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Duke Realty reports Q2 core FFO 32c, consensus 31c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ASGN

On Assignment

$51.71

-1.57 (-2.95%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
On Assignment reports Q2 EPS 62c, consensus 72c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ANIK

Anika Therapeutics

$47.99

-0.27 (-0.56%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Anika Therapeutics reports Q2 EPS 76c, consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

UVSP

Univest

$30.00

-0.3 (-0.99%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Breaking Earnings news story on Univest »

Univest reports Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Hot Stocks
Realty Income sees FY17 EPS $1.15-$1.20, consensus $1.22 »

Company estimates FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Whirlpool reports Q2 EPS $3.35, consensus $3.54 »

Reports Q2 revenue $5.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMO

Capstead Mortgage

$9.99

-0.06 (-0.60%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Capstead Mortgage reports Q2 EPS 14c, consensus 20c »

Book value per common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BPI

Bridgepoint Education

$12.29

-0.98 (-7.39%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Bridgepoint Education reports Q2 EPS 21c, consensus 23c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 10

    Aug

BDGE

Bridge Bancorp

$32.90

-0.7 (-2.08%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Breaking Earnings news story on Bridge Bancorp »

Bridge Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

QEP

QEP Resources

$9.27

0.07 (0.76%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
QEP Resources reports Q2 adjusted EPS (12c), consensus (20c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
Breaking Earnings news story on Monolithic Power »

Monolithic Power sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
UDR, Inc. backs FY17 EPS view of 31c-36c, consensus 28c »

Reaffirmed FFO per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FFIV

F5 Networks

$128.20

0.18 (0.14%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
F5 Networks sees Q4 non-GAAP EPS $2.20-$2.23, consensus $2.24 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 05

    Sep

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Monolithic Power reports Q2 EPS 68c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Realty Income reports Q2 EPS 30c, consensus 32c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FMNB

Farmers National Banc

$14.35

-0.4 (-2.71%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Farmers National Banc reports Q2 EPS 21c, consensus 22c »

Total loans were $1.51…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$43.86

-0.13 (-0.30%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Hot Stocks
Mercury Systems receives $5.5M order »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 07

    Aug

ESND

Essendant

$13.41

-0.42 (-3.04%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Essendant sees FY17 sales decline of 6%-9%, consensus $5.22B »

Management said, "In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.